Evolocumab in Patients Without Significant Atherosclerosis a -

Name: Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Uploaded: 2026-04-01T04:00:00+00:00
Description: In this activity, Dr. Nicholas Marston reviews a subgroup analysis of 3,655 patients from VESALIUS-CV trial, which evaluated evolocumab in high-risk

Home
Clinical Practice
Cardiology

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart Matters
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
- Joban Vaishnav, MD
Rethinking Thromboembolic Risk in ATTR-CM Care
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart Matters
Rethinking Thromboembolic Risk in ATTR-CM Care
Targeting Macrophages in Pulmonary Arterial Hypertension
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's Roundtable
Targeting Macrophages in Pulmonary Arterial Hypertension
Fatty Acid Profiles May Be Linked to PAH Risk
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstracts
Fatty Acid Profiles May Be Linked to PAH Risk
- Ryan Quigley

Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV

Recommended

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy